Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending:	O
___.	O
Chief	O
Complaint:	O
BRBPR	B-Lower_gastrointestinal_haemorrhage
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
None	O
History	O
of	O
Present	O
Illness:	O
___	O
year	O
old	O
female	O
hx.	O
Alzheimer's	B-Dementia
dementia,	B-Dementia
COPD,	O
HTN,	O
LLE	O
DVT,	O
multiple	O
CVAs	O
nonverbal	O
at	O
baseline	O
presenting	O
from	O
nursing	B-Lives_in_carehome
home	B-Lives_in_carehome
with	O
c/o	O
BRBPR.	B-Lower_gastrointestinal_haemorrhage
Patient	O
is	O
nonverbal	O
at	O
baseline.	O
As	O
per	O
report	O
from	O
nursing	B-Lives_in_carehome
home,	B-Lives_in_carehome
patient	O
had	O
bloody	B-Lower_gastrointestinal_haemorrhage
stool	B-Lower_gastrointestinal_haemorrhage
this	O
afternoon.	O
Labs	O
drawn	O
showed	O
hematocrit	O
of	O
21,	O
INR	O
of	O
6.5.	O
Patient	O
recieved	O
5mg	O
IM	O
vitamin	O
K	O
and	O
was	O
transferred	O
to	O
___	O
ED.	O
In	O
the	O
ED,	O
initial	O
VS:	O
96.6	O
72	O
100/42	O
(153/78	O
on	O
next	O
read)	O
18	O
97%.	O
Labs	O
were	O
notable	O
for	O
H/H	O
of	O
7.1/___.2,	O
chem-7	O
notable	O
for	O
BUN/Cr	O
of	O
60/1.4,	O
trop	O
t	O
0.03.	O
u/a	O
showed	O
large	O
leuks	O
and	O
nitrite	O
pos.	O
Patient	O
was	O
started	O
on	O
pantoprazole	O
drip,	O
was	O
ordered	O
for	O
2u	O
pRBCs,	O
2u	O
FFP,	O
given	O
ceftriaxone	O
x1.	O
GI	O
was	O
consulted.	O
Patient	O
is	O
being	O
transferred	O
to	O
the	O
MICU	O
for	O
close	O
monitoring.	O
On	O
arrival	O
to	O
the	O
MICU,	O
patient	O
remains	O
nonverbal.	O
Review	O
of	O
systems:	O
unable	O
to	O
be	O
obtained	O
Past	O
Medical	O
History:	O
Past	O
Medical	O
History	O
(as	O
per	O
prior	O
dc	O
summ	O
and	O
discussion	O
with	O
nursing	B-Lives_in_carehome
home):	B-Lives_in_carehome
-	O
mixed	O
dementia	B-Dementia
(Alzheimers	I-Dementia
and	O
Ischemic	O
Vascular	O
Disease)	O
-	O
T2DM,	O
on	O
insulin	O
-	O
HTN	O
-	O
s/p	O
multiple	O
CVAs	O
-	O
left	O
leg	O
DVT	O
on	O
coumadin	O
(dx	O
___	O
-	O
CKD	O
(baseline	O
Cr	O
1.2)	O
Social	O
History:	O
___	O
Family	O
History:	O
unable	O
to	O
obtain	O
Physical	O
Exam:	O
ADMISSION	O
EXAM	O
97.1	O
77	O
148/74	O
16	O
98%	O
RA	O
General-	O
eyes	O
closed,	O
lying	O
in	O
bed,	O
not	O
interactive	O
HEENT-	O
pupils	O
with	O
b/l	O
cataracts	B-Visual_impairment
Neck-	O
supple	O
Lungs-	O
mild	O
wheezing	O
anteriorly	O
CV-	O
RRR,	O
no	O
m/r/g	O
Abdomen-	O
soft,	O
nontender,	O
BS+	O
GU-	O
foley	O
in	O
place	O
Ext-	O
WWP,	O
no	O
c/c/e	O
Neuro-	O
uncooperative	O
DISCHARGE	O
EXAM	O
afebrile,	O
VSS	O
Lungs	O
clear	O
to	O
auscultation	O
bilaterally	O
Foley	O
catheter	O
removed	O
Remainder	O
of	O
exam	O
unchanged	O
Pertinent	O
Results:	O
ADMISSION	O
LABS	O
___	O
PLT	O
COUNT-263	O
NEUTS-37.6*	O
LYMPHS-51.7*	O
MONOS-6.9	O
EOS-3.3	O
BASOS-0.5	O
WBC-6.3	O
RBC-2.72*	O
HGB-7.1*	O
HCT-23.2*	O
MCV-86#	O
MCH-26.1*#	O
MCHC-30.5*#	O
RDW-13.4	O
CALCIUM-9.4	O
PHOSPHATE-4.2	O
MAGNESIUM-1.8	O
cTropnT-0.03*	O
GLUCOSE-107*	O
UREA	O
N-60*	O
CREAT-1.4*	O
SODIUM-143	O
POTASSIUM-5.4*	O
CHLORIDE-108	O
TOTAL	O
CO2-24	O
ANION	O
GAP-16	O
HGB-7.3*	O
calcHCT-22	O
LACTATE-1.6	O
K+-4.8	O
URINE	O
RBC-<1	O
WBC-34*	O
BACTERIA-MANY	O
YEAST-NONE	O
EPI-<1	O
___	O
PTT-70.2*	O
___	O
WBC-6.5	O
RBC-2.60*	O
HGB-6.7*	O
HCT-22.1*	O
MCV-85	O
MCH-26.0*	O
MCHC-30.5*	O
RDW-13.3	O
cTropnT-0.03*	O
GLUCOSE-108*	O
UREA	O
N-56*	O
CREAT-1.3*	O
SODIUM-143	O
POTASSIUM-5.4*	O
CHLORIDE-110*	O
TOTAL	O
CO2-21*	O
ANION	O
GAP-17	O
DISCHARGE	O
LABS	O
___:	O
Hematocrit	O
29	O
ferritin	O
17	O
MICRO	O
___	O
blood	O
culture-	O
coagulase	O
negative	O
Staph,	O
thought	O
to	O
be	O
contaminant,	O
as	O
all	O
other	O
blood	O
cultures	O
are	O
negative	O
or	O
pending,	O
and	O
there	O
were	O
no	O
signs	O
of	O
infection	O
urine	O
culture-	O
mixed	O
flora	O
REPORTS	O
___	O
Imaging	O
CT	B-Intracranial_haemorrhage
HEAD	B-Intracranial_haemorrhage
W/O	O
CONTRAST	O
FINDINGS:	O
Study	O
is	O
somewhat	O
motion	O
limited;	O
however,	O
there	O
is	O
no	O
evidence	O
of	O
hemorrhage,	B-Intracranial_haemorrhage
mass	O
effect,	O
shift	O
of	O
normally	O
midline	O
structures,	O
or	O
infarction.	O
Ventricles	O
and	O
sulci	O
are	O
enlarged	O
consistent	O
with	O
age-related	O
atrophy.	O
This	O
atrophy	O
has	O
progressed	O
substantially	O
since	O
the	O
study	O
of	O
___.	O
Gray-white	O
matter	O
differentiation	O
is	O
preserved	O
throughout.	O
The	O
sinuses	O
are	O
clear.	O
Carotid	O
siphon	O
as	O
well	O
as	O
vertebral	O
artery	O
calcifications	O
are	O
noted.	O
IMPRESSION:	O
No	O
evidence	O
hemorrhage	O
or	O
infarction.	O
Marked	O
progression	O
of	O
atrophy	O
since	O
___.	O
left	O
___:	O
no	O
DVT	O
in	O
left	O
lower	O
extremity	O
Brief	O
Hospital	O
Course:	O
___	O
year	O
old	O
female	O
with	O
advanced	O
Alzheimer's	B-Dementia
dementia/cerebrovascular	B-Dementia
disease	O
(aphasic	O
and	O
non-verbal	O
at	O
baseline),	O
COPD,	O
HTN,	O
remote	O
left	O
___	O
DVT,	O
presenting	O
from	O
nursing	B-Lives_in_carehome
home	B-Lives_in_carehome
with	O
c/o	O
BRBPR	B-Lower_gastrointestinal_haemorrhage
in	O
setting	O
of	O
INR	O
6.9.	O
#	O
GI	B-Upper_gastrointestinal_haemorrhage
bleed:	B-Upper_gastrointestinal_haemorrhage
nursing	B-Lives_in_carehome
home	B-Lives_in_carehome
reported	O
BRBPR	B-Lower_gastrointestinal_haemorrhage
concerning	O
for	O
lower	B-Lower_gastrointestinal_haemorrhage
GI	B-Lower_gastrointestinal_haemorrhage
bleed.	B-Lower_gastrointestinal_haemorrhage
Patient's	O
initial	O
hematocrit	O
was	O
21,	O
down	O
from	O
baseline	O
of	O
28	O
according	O
to	O
___	O
home	O
labs.	O
Received	O
total	O
of	O
3	O
units	O
of	O
PRBCs	O
and	O
2u	O
FFP	O
for	O
elevated	O
INR,	O
with	O
good	O
response.	O
No	O
recurrence	O
of	O
bleeding	O
during	O
admission,	O
and	O
discharge	O
hematocrit	O
29.	O
Coumadin	O
and	O
plavix	O
were	O
held,	O
and	O
Plavix	O
restarted	O
prior	O
to	O
discharge.	O
Discussed	O
case	O
with	O
HCP,	O
daughter	O
___,	O
and	O
Dr.	O
___,	O
who	O
is	O
the	O
physician	O
who	O
has	O
been	O
caring	O
for	O
patient	O
over	O
past	O
___	O
years	O
at	O
nursing	B-Lives_in_carehome
home,	B-Lives_in_carehome
and	O
decision	O
was	O
made	O
to	O
discontinue	O
warfarin,	O
as	O
DVT	O
was	O
remote,	O
and	O
risks	O
of	O
future	O
GI	B-Upper_gastrointestinal_haemorrhage
bleeds	B-Upper_gastrointestinal_haemorrhage
outweighed	O
benefit	O
of	O
ongoing	O
anticoagulation.	O
GI	O
was	O
consulted,	O
recommended	O
trending	O
hematocrit	O
and	O
conservative	O
management,	O
continuing	O
PPI	O
for	O
2	O
weeks	O
total,	O
and	O
to	O
monitor	O
CBC	O
once	O
per	O
week	O
for	O
the	O
next	O
2	O
weeks	O
to	O
ensure	O
stable	O
hematocrit.	O
Defer	O
to	O
Dr.	O
___	O
whether	O
to	O
start	O
DVT	O
prophylaxis	O
for	O
patient	O
in	O
the	O
future.	O
#	O
Hx.	O
DVT:	O
per	O
nursing	B-Lives_in_carehome
home,	B-Lives_in_carehome
dx	O
in	O
___.	O
On	O
warfarin	O
prior	O
to	O
admission,	O
with	O
supratherapeutic	O
IRN.	O
As	O
noted	O
above,	O
will	O
discontinue	O
warfarin.	O
Left	O
___	O
prior	O
to	O
discharge	O
negative	O
for	O
DVT.	O
#	O
UTI:	B-Urinary_tract_infection
patient	O
with	O
positive	O
u/a	O
in	O
ED.	O
Was	O
treated	O
with	O
empiric	O
course	O
of	O
ceftriaxone,	O
and	O
will	O
finish	O
with	O
Bactrim	O
on	O
___.	O
#	O
Cerebrovascular	O
disease-	O
held	O
Plavix	O
in	O
setting	O
of	O
GI	B-Upper_gastrointestinal_haemorrhage
bleed,	B-Upper_gastrointestinal_haemorrhage
restarted	O
prior	O
to	O
discharge	O
#	O
HTN:	O
held	O
home	O
antihypertensives	O
including	O
diltiazem,	O
metoprolol,	O
lisinopril,	O
and	O
furosemide	O
in	O
setting	O
of	O
GI	B-Upper_gastrointestinal_haemorrhage
bleed,	B-Upper_gastrointestinal_haemorrhage
all	O
restarted	O
prior	O
to	O
discharge	O
#	O
T2DM:	O
continued	O
home	O
lantus	O
regimen	O
30u	O
QAM	O
+	O
ISS	O
#	O
COPD:	O
continued	O
albuterol	O
TRANSITIONAL	O
ISSUES	O
-	O
check	O
CBC	O
once	O
per	O
week	O
with	O
results	O
to	O
Dr.	O
___,	O
to	O
ensure	O
stable	O
hematocrit	O
-	O
cont	O
pantoprazole	O
for	O
2	O
more	O
weeks,	O
then	O
discontinue	O
-	O
stop	O
warfarin	O
-	O
stop	O
enoxaparin-	O
defer	O
to	O
Dr.	O
___	O
starting	O
DVT	O
prophylaxis	O
in	O
the	O
future	O
-	O
please	O
resume	O
all	O
nursing	O
care	O
provided	O
at	O
___	O
___	O
and	O
___	O
that	O
was	O
provided	O
prior	O
to	O
admission	O
Daughter	O
___,	O
HCP,	O
at	O
___	O
was	O
updated	O
daily	O
and	O
of	O
day	O
of	O
discharge,	O
agreed	O
with	O
plan,	O
and	O
did	O
not	O
have	O
any	O
questions	O
or	O
concerns.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Clopidogrel	O
75	O
mg	O
PO	O
DAILY	O
2.	O
Lisinopril	O
20	O
mg	O
PO	O
DAILY	O
3.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
PO	O
BID	O
4.	O
Docusate	O
Sodium	O
200	O
mg	O
PO	O
DAILY	O
5.	O
Diltiazem	O
60	O
mg	O
PO	O
Q8H	O
6.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
7.	O
Enoxaparin	O
Sodium	O
60	O
mg	O
SC	O
DAILY	O
Start:	O
___,	O
First	O
Dose:	O
Next	O
Routine	O
Administration	O
Time	O
8.	O
Senna	O
2	O
TAB	O
PO	O
BID:PRN	O
constipation	B-Constipation
9.	O
Albuterol	O
Inhaler	O
2	O
PUFF	O
IH	O
Q4H:PRN	O
wheeze	O
10.	O
Warfarin	O
7.5	O
mg	O
PO	O
DAILY16	O
11.	O
Glargine	O
30	O
Units	O
Breakfast	O
Insulin	O
SC	O
Sliding	O
Scale	O
using	O
REG	O
Insulin	O
Discharge	O
Medications:	O
1.	O
Albuterol	O
Inhaler	O
2	O
PUFF	O
IH	O
Q4H:PRN	O
wheeze	O
2.	O
Clopidogrel	O
75	O
mg	O
PO	O
DAILY	O
3.	O
Diltiazem	O
60	O
mg	O
PO	O
Q8H	O
4.	O
Docusate	O
Sodium	O
200	O
mg	O
PO	O
DAILY	O
5.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
6.	O
Glargine	O
30	O
Units	O
Breakfast	O
Insulin	O
SC	O
Sliding	O
Scale	O
using	O
HUM	O
Insulin	O
7.	O
Lisinopril	O
20	O
mg	O
PO	O
DAILY	O
8.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
PO	O
BID	O
9.	O
Senna	O
2	O
TAB	O
PO	O
BID:PRN	O
constipation	B-Constipation
10.	O
Outpatient	O
Lab	O
Work	O
please	O
check	O
CBC	O
on	O
___	O
and	O
___	O
and	O
contact	O
Dr.	O
___	O
with	O
results.	O
11.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q24H	O
Duration:	O
2	O
Weeks	O
12.	O
Sulfameth/Trimethoprim	O
DS	O
1	O
TAB	O
PO	O
BID	O
Duration:	O
3	O
Days	O
last	O
day	O
___	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Primary	O
diagnoses:	O
GI	B-Upper_gastrointestinal_haemorrhage
bleed,	B-Upper_gastrointestinal_haemorrhage
likely	O
lower	O
in	O
etiology,	O
in	O
setting	O
of	O
supratherapeutic	O
INR	O
(6.9)	O
Cerebrovascular	O
disease,	O
chronic,	O
with	O
aphasia	O
(patient	O
non-verbal	O
at	O
baseline)	O
Secondary	O
diagnoses:	O
insulin-dependent	O
diabetes	O
hypertension	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Confused	B-Delirium
-	O
always.	O
Level	O
of	O
Consciousness:	O
non-verbal	O
at	O
baseline,	O
interactive	O
at	O
times	O
with	O
family	O
Activity	O
Status:	O
Bedbound.	B-Bed_Chairbound
Discharge	O
Instructions:	O
Patient	O
admitted	O
to	O
ICU	O
for	O
management	O
of	O
GI	B-Upper_gastrointestinal_haemorrhage
bleed	B-Upper_gastrointestinal_haemorrhage
in	O
setting	O
of	O
supratherapeutic	O
INR	O
(6.9).	O
Received	O
FFP	O
for	O
reversal,	O
and	O
total	O
of	O
3	O
units	O
of	O
PRBCs,	O
with	O
good	O
response.	O
Patient	O
evaluated	O
by	O
GI,	O
and	O
given	O
no	O
recurrence	O
of	O
bleeding	O
throughout	O
hospitalization	O
and	O
advanced	O
dementia,	B-Dementia
conservative	O
approach	O
was	O
pursued,	O
and	O
colonoscopy	O
deferred.	O
Hematocrit	O
at	O
discharge	O
was	O
29.	O
Discussed	O
case	O
with	O
Dr.	O
___	O
has	O
been	O
caring	O
for	O
patient	O
at	O
___	O
home	O
for	O
past	O
___	O
years,	O
and	O
decision	O
was	O
made	O
to	O
discontinue	O
warfarin,	O
as	O
DVT	O
was	O
over	O
six	O
months	O
ago,	O
and	O
risks	O
of	O
future	O
bleeding	O
outweigh	O
risks	O
of	O
new	O
DVT.	O
Left	O
___	O
negative	O
for	O
DVT	O
prior	O
to	O
discharge.	O
See	O
below	O
for	O
medication	O
list	O
and	O
recommendations	O
for	O
follow	O
up	O
lab	O
work.	O
Followup	O
Instructions:	O
___	O

